Post-Transplantation Survival and Relapse
GVHD
DISEASE, GVHD
The median OS landmarked to the date of HSCT was 16.1 months in the gilteritinib arm and 15.3 months in the SC arm (HR, 1.076; 95% CI, .536 to 2.160) (Among gilteritinib arm patients who were alive and without relapse for 60 days after HSCT, the median OS land-marked from post-transplantation day 60 had not been reached at the time of data cutoff in patients who resumed gilteritinib after HSCT (95% CI, 10.6 months to not reached). The median OS in patients who did not resume gilteritinib therapy was 10.1 months (95% CI, 2.8 to 19.3 months) (The reasons for not resuming gilteritinib after HSCT in 17 patients included progressive disease in 5, physician decision due to failure to meet protocol-defined criteria for restarting gilteritinib in 4, relapse in 2, lack of efficacy in 2, AEs in 1, GVHD in 1, CRc for >90 days after HSCT in 1, and lack of post-transplantation bone marrow, ANC, or platelet assessment and subsequent platelet transfusion in 1.